Piper Sandler Maintains Overweight on Zura Bio, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi has reiterated an Overweight rating on Zura Bio (NASDAQ:ZURA) and maintained a price target of $26.

September 19, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler's analyst Yasmeen Rahimi has reiterated an Overweight rating on Zura Bio, maintaining a price target of $26. This suggests confidence in Zura Bio's potential for growth.
The reaffirmation of an Overweight rating and a $26 price target by Piper Sandler indicates a positive outlook on Zura Bio's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100